great find. The clarification of 12% to 75% survival of the ventilator patients, makes things murky. MSBs 10/12 seems not that great now. This just illustrates the need for this clinical trial. A bit annoying that the JAMA article l was so far of the mark, it can be understood why as 4th April is such a long time ago and at the same time so early in terms of the New York part of this pandemic.
I am changing my sentiment.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-709
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 45345 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 3875 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |